Eli Lilly showcases Imlunestrant, Olomorasib, and ADC advancements at ASCO 2025

Eli Lilly and Company announced that data from studies of imlunestrant, an investigational oral selective estrogen receptor degrader (SERD), olomorasib, an investigational KRAS G12C inhibitor, LY4170156, an investigational antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα) and Verzenio^® (abemaciclib; a CDK4/6 inhibitor) will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 – June 3 in Chicago.

Presentation Highlights
Imlunestrant (investigational oral SERD)
In an oral presentation, Lilly will share patient-reported outcomes (PROs) from the Phase 3 EMBER-3 trial in patients with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC), and a poster presentation will feature expanded EMBER-3 safety analyses.

Olomorasib (investigational KRAS G12C inhibitor):
In two oral presentations, Lilly will report updated results from a Phase 1/2 study of olomorasib, a potent and highly selective second-generation inhibitor of KRAS G12C with preliminary evidence of CNS activity, in combination with pembrolizumab in patients with KRAS G12C-mutant advanced non-small cell lung cancer (NSCLC) and in combination with cetuximab in patients with KRAS G12C-mutant colorectal cancer (CRC). The submitted abstracts utilized a November 13, 2024 data cut-off date, and the presentations will utilize a January 15, 2025 data cut-off date.

LY4170156 (investigational ADC targeting FRα):
In a poster presentation, Lilly will report initial results from the multicenter, open-label, first-in-human Phase 1a/1b study of LY4170156 in patients with platinum-resistant ovarian cancer (PROC). LY4170156 is an Fc-silent, FRα specific humanized monoclonal antibody linked to exatecan, a topoisomerase I inhibitor, via a proprietary cleavable polysarcosine linker. The submitted abstract utilized a November 27, 2024 data cut-off date, and the poster will utilize a March 9, 2025 data cut-off date.

A full list of abstract titles and viewing details are listed below:

Imlunestrant (investigational oral SERD):
Presentation Title: Patient-reported outcomes (PROs) in patients with ER+, HER2- advanced breast cancer (ABC) treated with imlunestrant, investigator’s choice standard endocrine therapy, or imlunestrant + abemaciclib: Results from the phase III EMBER-3 trial
Abstract Number: 1001
Session Date & Time: Saturday, May 31, 1:15-4:15 p.m. CDT
Session Title: Breast Cancer – Metastatic
Location: Hall B1 | Live Stream
Presenter: Giuseppe Curigliano

Presentation Title: Imlunestrant with or without abemaciclib in advanced breast cancer (ABC): Safety analyses from the phase III EMBER-3 trial
Abstract Number: 1060
Session Date & Time: Monday, June 2, 9 a.m.-12 p.m. CDT
Session Title: Breast Cancer – Metastatic
Location: Hall A – Posters and Exhibits | On Demand
Presenter: Joyce O’Shaughnessy

Olomorasib (investigational KRAS G12C inhibitor):
Presentation Title: Efficacy and safety of olomorasib, a second-generation KRAS G12C inhibitor, plus cetuximab in KRAS G12C-mutant advanced colorectal cancer
Abstract Number: 3507
Session Date & Time: Friday, May 30, 2:45-5:45 p.m. CDT
Session Title: Gastrointestinal Cancer – Colorectal and Anal
Location: Arie Crown Theater | Live Stream
Presenter: Antoine Hollebecque

Presentation Title: Safety and efficacy of olomorasib + immunotherapy in first-line treatment of patients with KRAS G12C-mutant advanced NSCLC: Update from the LOXO-RAS-20001 trial
Abstract Number: 8519
Session Date & Time: Monday, June 2, 8-9:40 a.m. CDT
Session Title: Lung Cancer – Non-Small Cell Metastatic
Location: Arie Crown Theater | Live Stream
Presenter: Alexander I. Spira

LY4170156 (investigational ADC targeting FRα):
Presentation Title: Initial results from a first-in-human phase 1 study of LY4170156, an ADC targeting folate receptor alpha (FRα), in advanced ovarian cancer and other solid tumors
Abstract Number: 3023
Session Date & Time: Monday, June 2, 1:30-4:30 p.m. CDT
Session Title: Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology
Location: Hall A – Posters and Exhibits | On Demand
Presenter: Isabelle Ray-Coquard

Verzenio (abemaciclib):
Presentation Title: Impact of body mass index (BMI) on efficacy and safety of abemaciclib in breast cancer patients (pts) treated in the monarchE trial
Abstract Number: 520
Session Date & Time: Monday, June 2, 9 a.m.-12 p.m. CDT
Session Title: Breast Cancer – Local/Regional/Adjuvant
Location: Hall A – Posters and Exhibits | On Demand
Presenter: Christine Desmedt

For more information on Lilly’s Oncology pipeline click here.